These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19461676)

  • 21. [Soluble expression of recombinant immunotoxin against human bladder carcinoma and its anti-tumor activity].
    Chao K; He D; Yang H; Zhang Z; Lin Q; Guo AG; Huang HL
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Sep; 20(5):568-71. PubMed ID: 15367349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.
    Bruell D; Bruns CJ; Yezhelyev M; Huhn M; Müller J; Ischenko I; Fischer R; Finnern R; Jauch KW; Barth S
    Int J Mol Med; 2005 Feb; 15(2):305-13. PubMed ID: 15647848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model.
    Kreitman RJ; Chang CN; Hudson DV; Queen C; Bailon P; Pastan I
    Int J Cancer; 1994 Jun; 57(6):856-64. PubMed ID: 8206679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary T cells for mRNA-mediated immunotoxin delivery.
    Eggers R; Philippi A; Altmeyer MO; Breinig F; Schmitt MJ
    Gene Ther; 2018 Jan; 25(1):47-53. PubMed ID: 28937681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation.
    Kuan CT; Pastan I
    Biochemistry; 1996 Mar; 35(9):2872-7. PubMed ID: 8608123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins.
    Hexham JM; Dudas D; Hugo R; Thompson J; King V; Dowling C; Neville DM; Digan ME; Lake P
    Mol Immunol; 2001 Sep; 38(5):397-408. PubMed ID: 11684296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model.
    Gattenlöhner S; Jörissen H; Huhn M; Vincent A; Beeson D; Tzartos S; Mamalaki A; Etschmann B; Muller-Hermelink HK; Koscielniak E; Barth S; Marx A
    J Biomed Biotechnol; 2010; 2010():187621. PubMed ID: 20204062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer.
    Bera TK; Williams-Gould J; Beers R; Chowdhury P; Pastan I
    Mol Cancer Ther; 2001 Dec; 1(2):79-84. PubMed ID: 12467225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [High level expression, purification and cytotoxicity of IL-10(18-57)-PE40].
    Peng QS; Li YH; Zhu P
    Sheng Wu Gong Cheng Xue Bao; 2006 Jan; 22(1):87-93. PubMed ID: 16572846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A chemical conjugate between HER2-targeting antibody fragment and Pseudomonas exotoxin A fragment demonstrates cytotoxic effects on HER2-expressing breast cancer cells.
    Lee S; Park S; Nguyen MT; Lee E; Kim J; Baek S; Kim CJ; Jang YJ; Choe H
    BMB Rep; 2019 Aug; 52(8):496-501. PubMed ID: 30670149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotoxin-mediated targeting of claudin-4 inhibits the proliferation of cancer cells.
    Hashimi SM; Yu S; Alqurashi N; Ipe DS; Wei MQ
    Int J Oncol; 2013 Jun; 42(6):1911-8. PubMed ID: 23563899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.
    Cerise A; Bera TK; Liu X; Wei J; Pastan I
    Clin Colorectal Cancer; 2019 Sep; 18(3):192-199.e1. PubMed ID: 31345777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen.
    Francisco JA; Gilliland LK; Stebbins MR; Norris NA; Ledbetter JA; Siegall CB
    Cancer Res; 1995 Jul; 55(14):3099-104. PubMed ID: 7541711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.
    Onda M; Beers R; Xiang L; Lee B; Weldon JE; Kreitman RJ; Pastan I
    Proc Natl Acad Sci U S A; 2011 Apr; 108(14):5742-7. PubMed ID: 21436054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL.
    Liu Z; Feng Z; Zhu X; Xu W; Zhu J; Zhang X; Fan Z; Ji G
    Immunol Lett; 2013 Jan; 149(1-2):30-40. PubMed ID: 23026237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.
    Baiz D; Hassan S; Choi YA; Flores A; Karpova Y; Yancey D; Pullikuth A; Sui G; Sadelain M; Debinski W; Kulik G
    Neoplasia; 2013 Oct; 15(10):1172-83. PubMed ID: 24204196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The immunotoxin activity of exotoxin A is sensitive to domain modifications.
    Amiri Tehranizadeh Z; Sankian M; Fazly Bazzaz BS; Chamani J; Mehri S; Baratian A; Saberi MR
    Int J Biol Macromol; 2019 Aug; 134():1120-1131. PubMed ID: 31129209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis.
    Sokolova E; Guryev E; Yudintsev A; Vodeneev V; Deyev S; Balalaeva I
    Oncotarget; 2017 Mar; 8(13):22048-22058. PubMed ID: 28423549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells.
    Wolf P; Gierschner D; Bühler P; Wetterauer U; Elsässer-Beile U
    Cancer Immunol Immunother; 2006 Nov; 55(11):1367-73. PubMed ID: 16547705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.
    Niesen J; Stein C; Brehm H; Hehmann-Titt G; Fendel R; Melmer G; Fischer R; Barth S
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2079-95. PubMed ID: 25899161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.